Primary Endpoints

Egetis Therapeutics AB (publ)

20/06/2024 07:34

June 20 (Reuters) - Egetis Therapeutics AB  EGTX.ST :
    * SAID ON WEDNESDAY PHASE 2 TRIAC TRIAL II FOR
INVESTIGATIONAL
DRUG EMCITATE (TIRATRICOL) IN TREATMENT OF MONOCARBOXYLATE
TRANSPORTER 8 (MCT8) DEFICIENCY DID NOT MEET ITS CO-PRIMARY
ENDPOINTS
    * NUMERICAL IMPROVEMENTS VERSUS BASELINE OBSERVED ON PRIMARY
ENDPOINTS OF NEUROCOGNITIVE DEVELOPMENT ASSESSED BY GMFM-88 AND
BSID-III SCALES DID NOT SHOW STATISTICALLY SIGNIFICANT
IMPROVEMENT VERSUS HISTORICAL CONTROLS
    * TRIAC TRIAL II WAS FOR YOUNG PATIENTS WHO WERE LESS THAN
30
MONTHS OF AGE AT START OF TRIAL
    * TRIAL CONFIRMED WELL-TOLERATED SAFETY PROFILE SEEN IN
PREVIOUS
CLINICAL STUDIES
    * COMPANY DOES NOT CONSIDER APPROVABILITY OF PRODUCT TO BE
AFFECTED BY TRIAC TRIAL II RESULTS AND REGULATORY TIMELINES
REMAIN UNCHANGED

        
 Source text for Workspace:  urn:newsml:reuters.com:*:nMFN6JPrv4
 Further company coverage:  EGTX.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))